Linda J. Peters — Executive VP & Chief Regulatory Officer at Becton Dickinson

Ms. Linda J. Peters serves as the Executive Vice President and Chief Regulatory Officer at Becton, Dickinson and Company. Ms. Peters has been Senior Vice President of Client Services at Kinsale Holdings, Inc. since February 2016. Ms. Peters served as Senior Vice President of Regulatory Affairs at MedImmune, LLC since February 22, 2005 and was responsible for defining and orchestrating its global regulatory strategy. Ms. Peters served as Vice President of Global Regulatory Affairs for the Bioscience and Renal Divisions at Baxter Healthcare. While at Baxter, she was responsible for implementing global regulatory strategies for biologics, vaccines, drugs, biosurgical products and devices, which included several new product approvals worldwide. Previously, Ms. Peters served as Director of regulatory affairs for Takeda Pharmaceuticals North America where she was responsible for the regulatory management of more than a dozen new compounds and marketed products. As the first regulatory affairs scientist at Takeda, she created a regulatory vision for Medimmune, Inc. and successfully established a department of more than 30 regulatory professionals in less than three years. Ms. Peters was also involved with the U.S. approval and launch of ACTOS (pioglitazone HCl), a drug for the treatment of Type II diabetes. In addition, she held positions of increasing responsibility at TAP Pharmaceuticals, which included regulatory approval for several new indications for PRECAVID (lansoprazole), an anti- ulcer drug. She served as a Director of Sequoia Pharmaceuticals, Inc. since January 2007 until January 2010. Ms. Peters holds a Bachelor of Science and Master of Science in animal science from Southern Illinois University. She also holds an Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University.